{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:37:41Z","timestamp":1785292661095,"version":"3.55.0"},"reference-count":18,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,7,28]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In locally recurrent rectal cancer (LRRC), surgery is a standard treatment for resectable disease. However, short-term and long-term outcomes are unsatisfactory due to the invasive nature of surgical procedures and the high proportion of local recurrence. Consequently, the identification of reliable prognostic and predictive biomarkers to guide treatment decisions may improve outcomes. The presence of circulating tumour DNA (ctDNA) in plasma after surgery may signify the presence of minimal residual disease (MRD) in various cancers. Therefore, we have launched a multi-institutional prospective observational study of ctDNA for MRD detection in conjunction with JCOG1801, a randomised, controlled phase III trial evaluating the efficacy of preoperative chemoradiotherapy (pre-CRT) compared with up-front surgery for LRRC (jRCTs031190076,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04288999\">NCT04288999<\/jats:ext-link>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>JCOG1801A1 is the first correlative study that assesses ctDNA in LRRC patients enrolled in JCOG1801. Patients randomised to up-front surgery will provide whole blood samples at three time points (prior to surgery, after surgery and after postoperative chemotherapy); those to pre-CRT will provide at five time points (prior to pre-CRT, after pre-CRT, prior to surgery, after surgery and after postoperative chemotherapy). Cell-free DNA will be extracted from plasma and analysed by Guardant Reveal, a tumour tissue\u2013agnostic assay that assesses both genomic alterations and methylation patterns to determine the presence or absence of ctDNA. We will compare the prognosis and treatment response of patients according to their ctDNA status after surgery and at other time points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study protocol received approval from the Institutional Review Board of National Cancer Center Hospital East on behalf of the participating institutions in February 2023. The study is conducted in accordance with the precepts established in the Declaration of Helsinki and Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Written informed consent will be obtained from all eligible patients prior to registration.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-073217","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T17:36:21Z","timestamp":1692207381000},"page":"e073217","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study)"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04288999","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04288999","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04288999","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-1214","authenticated-orcid":false,"given":"Tadayoshi","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-2707","authenticated-orcid":false,"given":"Masaaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kanato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2024111400202860000_13.8.e073217.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2024111400202860000_13.8.e073217.2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0032"},{"key":"2024111400202860000_13.8.e073217.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1101-6"},{"key":"2024111400202860000_13.8.e073217.4","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199602000-00010"},{"key":"2024111400202860000_13.8.e073217.5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/bjs.9192","article-title":"Consensus statement on the Multidisciplinary management of patients with recurrent and primary Rectal cancer beyond total Mesorectal Excision planes","volume":"100","year":"2013","journal-title":"Br J Surg"},{"key":"2024111400202860000_13.8.e073217.6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jjco\/hyaa058","article-title":"A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan clinical oncology group study Jcog1801 (RC-SURVIVE study)","volume":"50","author":"Kadota","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2024111400202860000_13.8.e073217.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1063-5"},{"key":"2024111400202860000_13.8.e073217.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.009"},{"key":"2024111400202860000_13.8.e073217.9","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024111400202860000_13.8.e073217.10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"2024111400202860000_13.8.e073217.11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024111400202860000_13.8.e073217.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4769"},{"key":"2024111400202860000_13.8.e073217.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2299"},{"key":"2024111400202860000_13.8.e073217.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PLoS Med"},{"key":"2024111400202860000_13.8.e073217.15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315852"},{"key":"2024111400202860000_13.8.e073217.16","first-page":"760","article-title":"Circulating tumor DNA guiding adjuvant therapy in colon cancer. Reply","volume":"387","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"2024111400202860000_13.8.e073217.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520"},{"key":"2024111400202860000_13.8.e073217.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0410"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-073217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:22:00Z","timestamp":1731572520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-073217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjopen-2023-073217"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-073217","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}